Evidence map›Paper›PMID 41382207›Full record

ReviewEpigenetics & chromatin2025

Research advances in epigenetic modifications and post-translational modifications in endothelial-mesenchymal transition.

Zhongjun Shen, Shuo Yang, Qian Zhang, Qi Liu, He Wang, Jingjin Tao, Zhongxin Li, Chong Wang, Yuying Nie, Xiangyi Xu and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Epigenetics & chromatin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhongjun ShenInstitute of Medical Technology, Peking University Health Science Center, Beijing, China.
Shuo YangDepartment of Clinical Laboratory, Peking University Third Hospital, Beijing, China.
Qian ZhangDepartment of Clinical Laboratory, Peking University Third Hospital, Beijing, China.
Qi LiuDepartment of Clinical Laboratory, Peking University Third Hospital, Beijing, China.
He WangDepartment of Clinical Laboratory, Peking University Third Hospital, Beijing, China.
Jingjin TaoInstitute of Medical Technology, Peking University Health Science Center, Beijing, China.
Zhongxin LiDepartment of Clinical Laboratory, Peking University Third Hospital, Beijing, China.
Chong WangDepartment of Clinical Laboratory, Peking University Third Hospital, Beijing, China.
Yuying NieDepartment of Clinical Laboratory, Peking University Third Hospital, Beijing, China.
Xiangyi XuInstitute of Medical Technology, Peking University Health Science Center, Beijing, China.
Huike GuoInstitute of Medical Technology, Peking University Health Science Center, Beijing, China.
Liyan CuiInstitute of Medical Technology, Peking University Health Science Center, Beijing, China. cliyan@163.com.

Funding

the National Natural Science Foundation of China 62071011
6 · The paper itself

Abstract

Endothelial-mesenchymal transition (EndMT) is a biological process in which endothelial cells lose intercellular junctions and endothelial characteristics under specific pathophysiological stimuli and acquire mesenchymal traits. It plays a critical role in cardiac development, tissue fibrosis, tumor metastasis, atherosclerosis, and other diseases. In recent years, growing evidence has demonstrated that epigenetic modifications and post-translational modifications are central to the precise regulation of EndMT initiation and progression. This review systematically elaborates on how epigenetic mechanisms-such as DNA methylation, histone modifications, and non-coding RNAs-as well as post-translational modifications, including protein phosphorylation, acetylation, and ubiquitination, regulate EndMT by modulating key signaling pathways (e.g., TGF-β, Wnt, Notch) and transcription factors (e.g., Snail, Slug, Twist, ZEB1/2). A deeper understanding of these regulatory networks may provide novel diagnostic biomarkers and therapeutic strategies for diseases targeting EndMT.

Indexed as

Endothelial CellsEpigenesis, GeneticEpithelial-Mesenchymal TransitionProtein Processing, Post-TranslationalAnimalsDNA MethylationEndothelial-Mesenchymal TransitionHistone CodeHistonesHumansSignal TransductionTranscription FactorsHistonesTranscription FactorsDNA methylationEndothelial-mesenchymal transitionEpigenetic modificationsHistone modificationsNon-coding RNAPost-translational modifications

Identifiers

PMID41382207
PMCPMC12699931

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.